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During the current work, we synthesized a new peptide derivative; 4,13-diisopropyl-2,5,12,15-tetraoxo-3,6,11,14-
tetraaza-1(3,5)-pyridinacyclopentadecaphane-7-carbohydrazide. The prepared hydrazide was investigated for its in vivo as 
well as in vitro anticancer effects. Results revealed that this derivative has a great potential against 6 cancerous cell lines. 
Furthermore, the highest effect was obtained against HT1080 and HeLa cells, where the compound showed 7.4- and 15.1-
folds increased activity against them, respectively. Additionally, the compound seems to exert its potential anticancer effect 
by affecting the kinase enzyme VEGFR-2. Finally, the compound showed promising results when tested in in vivo against 
prostate cancer developed animal models. 
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Introduction 
From thirty years ago, peptide magainin was 
discovered and used as anticancer agent1,2, and thus, 
attention was directed towards the anticancer 
activities of a wide range of host defense peptides  
of the innate immune system.3–5 In our previous 
work6–13, we reported that certain of newly 
synthesized compounds incorporated heterocyclic 
and amino acid moieties exhibited antimicrobial, 
6–9antiinflammatory10, anticancer12, and Monoamino 
oxidase inhibitors13 activities. On the other hand, 
carbohydrazide derivative were synthesized and 
evaluated as potential antitumor activity.14 In 
addition, some of substituted macrocyclic peptide 
derivatives were evaluated for Topoisomerase I and 
II inhibitory activity15, cytotoxicity against several 
human cancer cell lines16,17 and kinase inhibitory 
activities.18 In this study, we reported the in vitro 
anti-VEGFR-2 kinase activity, in vitro cytotoxicity 
as well as in vivo antiprostate effects of the  
newly synthesized macrocyclic tripeptidopyridine 
candidate. 
Materials and methods 
 
Reagents 
3,5-Pyridinedicarbonylchloride was prepared and 
elucidated according to literature procedures.11  
L-Valene, methanol, dichloromethane, hydrazine 
hydrate, and L-lornithine methyl estere, were all 
purchased from Sigma-Aldrich (Switzerland). Melting 
point was determined in Electro Thermal Digital 
melting point apparatus IA9100. IR (KBr) spectra were 
recorded on a Nexus 670 FTIR Fourier Transform 
infrared spectrometer. 1H NMR and 13C NMR spectra 
were recorded in DMSO-d6 on a JEOL 500 MHz 
instrument (Tokyo, Japan). Mass spectra were run on a 
MAT Finnigan SSQ 7000 spectrometer (Shimadzu, 
Kyoto, Japan; Model: QP2010 ultra), using the electron 
impact technique (EI). The compound 5 was previously 
characterized by physical and spectroscopic data which 
were reported by Amr et al.11. 
 
Synthesis of 4,13-diisopropyl-2,5,12,15-tetraoxo-3,6,11,14-
tetraaza-1(3,5)-pyridinacyclopentadecaphane-7-carbohydrazide 5 
To a solution of methyl 4,13-diisopropyl- 
2,5,12,15-tetraoxo-3,6,11,14-tetraaza-1(3,5)-pyridin- 
acyclopentadecaphane-7-carboxylate (4) (0.475 g,  *Author for Correspondence E-mail: eaelsayed@ksu.edu.sa 
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1 mmol) in absolute methanol (25 mL), hydrazine 
hydrate (0.8 mL, 16 mmol) was added with stirring. 
The reaction mixture was heated under reflux for 6 h, 
and then evaporated to dryness under vacuum. The 
formed residue was washed with diethyether several 
times, filtered off, and crystallized from dioxane-
water to afford the corresponding cyclo hydrazide 
derivative 5. The obtained compound 5 was compared 
with authentic sample previously prepared and 
characterized by Amr et al.11 
 
Biological Activities  
 
Effect of the prepared hydrazide on cancer cell viability 
The prepared hydrazide was tested for its effect on 
viability of 17 cancerous cell lines covering almost all 
important cancer types.21,22 The assay was performed 
according to our previously developed protocol using 
standard MTT assay method.  
 
Effect of compound 5 on kinase inhibition  
The method used throughout the work was adopted 
from our previously optimized and published protocol 
depending on ELISA.22 
 
Antiprostate cancer animal model investiagtion 
In our previous work22, we used male Wistar rats to 
initiate and evaluate prostate cancer as affected by our 
synthesized hydrazide. Our experimental protocol was 
strictly followed for evaluating the degree of affecting 
prostate cancer in animal models. 
 
Result and Discussion 
 
Chemistry 
We have previously synthesized some 
macrocyclic tripeptidopyridine candidate 5 and  
they characterized by physical, chemical and 
spectroscopic evidences in advance according to  
our previous work.11 Macrocyclic tripeptide 5  
was synthesized by using methyl 4,13- 
diisopropyl-2,5,12,15-tetraoxo-3,6,11,14-tetraaza-
1(3,5)-pyridinacyclopentadecaphane-7-carboxylate 
(4) as starting materials, which was synthesized from 
3,5-pyridine dicarbonyl dichloride 1, according to a 
reported procedure.19,20 Reaction of dipeptide 3 with 
L-ornithine methyl ester by using azide method 
afforded cyclic derivative4, which was treated with 
NH2NH2.H2O to give cyclic tripeptide hydrazide 5 
(Scheme 1). In the current study, we report the 
evaluation and activities of this compound as 
possible anticancer agents. 
 
Biological Screening 
 
Effect of compound 5 on the viability of different cancer cell lines 
The second section of the current work was 
designed to evaluate the possible effects of the 
prepared cyclo (Nα-pyrido)-bis-[(L-valinyl)-L-
ornthenyl acid hydrazide] on the viability of different 
cancer cell lines. The results were obtained with 
positive drug controls. The obtained results, presented 
in Fig. 1, showed that the effect of compound 5 on 
cancer cell lines can be classified into three different 
categories. Firstly, compound 5 exhibited more or less 
similar effects in comparison to positive controls 
against cervical carcinoma (KB) and the melanoma 
G361 cell lines. The obtained IC50 values recorded 
4.45 and 6.78 nM for KB and G361 cells, 
respectively, while their corresponding positive 
controls showed IC50 values of 4.46 and 6.66 nM for 
Fluorouracil and Aldesleukin, respectively. On the 
other hand, compound 5 showed potential anticancer 
activities against prostate cancer cell line (PC-3), liver 
carcinoma (HepG2), leukemia (K561), colon 
adenocarcinoma (RKOP27), fibrosarcoma (HT1080) 
and the cervical carcinoma (HeLa) cell lines. 
However, comparing the obtained results with their 
corresponding positive controls, revealed that cells 
were differently affected with the tested compound. 
The obtained IC50 values against PC3 and HepG2 
cells increased by about 15.8 and 19.2% from their 
corresponding positive controls (6.92 and 2.78 nM for 
PC3 and HepG2 cells, respectively, and 8.22 and  
3.44 nM for Bicalutamide and Gemcitabine, 
respectively. For, K561 and RKOP27 cells, the 
obtained IC50 (3.35 and 1.54 nM, respectively) 
increased by about 49.7 and 64.4%, respectively, from 
their positive controls (6.66 and 4.33 nM for 
Doxorubicin and Capecitabine, respectively. The most 
prominent effect was obtained against HT1080 and 
HeLa cells, where there was an increased cytotoxic 
effect of about 7.4- and 15.1-folds from their positive 
controls. Regarding ovarian carcinoma (SKOV-3), 
CNS cancer (SF-268), non-small lung cancer (NCI 
H460), leukemia (HL60 and U937), melanoma  
(SK-MEL-28), neuroblastoma (GOTO and NB-1), 
breast carcinoma (MCF-7), it can be seen that 
although these cell lines were also affected by the 
prepared compound (5), however, the obtained IC50 
values for them were much lower than their 
corresponding positive controls as shown in Fig. 1. 
Generally, different cells react differently towards 
affecting compounds of natural extracts due to their  
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Scheme 1 — Synthetic pathway for compound 5 
 
  
Fig. 1 — Anti-VEGFR-2 activity of the synthesized compound 5 
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built-in differences in membrane structure and 
organization.23,24 
 
In vitro anti-VEGFR-2 screening 
The prepared compound (Cpd. 5) was evaluated for 
its inhibitory effect of VEGFR-2 kinase activity in 
order to have an estimated idea about its possible 
mechanism of action. Results showed that the 
prepared cyclo (Nα-pyrido)-bis-[(L-valinyl)-L-
ornthenyl acid hydrazide] showed increased inhibitory 
effect against VEGFR-2 kinase enzyme, where the 
inhibitory effect obtained (IC50 = 1.33 nM) was about 
33.5% higher than the effect obtained by the positive 
control (Sorafenib, IC50 = 2 nM).  
 
In vivo antiprostate cancer activity 
Finally, the potential of the prepared cyclo (Nα-
pyrido)-bis-[(L-valinyl)-L-ornthenyl acid hydrazide] 
to exhibit antitumorigenic effects in animal model 
was evaluated against in vivo antiprostate cancer 
developed in mice. In terms of ED50 value, Cpd. 5 
showed a potential antitumorigenic activity  
(ED50 = 1.65 ± 0.021 μM), which was about  
7-folds higher than the obtained results for Flutamide 
(ED50 = 11.60 ± 0.09 μM). 
 
Conclusion 
We reported the potential in vitro and in vivo 
anticancer activities of a newly synthesized cyclo  
(Nα-pyrido)-bis-[(L-valinyl)-L-ornthenyl acid 
hydrazide]. Results showed that the prepared 
compound can adversely affect the viability of all 
tested cancerous cell lines with variable extents. 
Additionally, the newly prepared hydrazide may 
affect the viability of cancerousss cells by interfering 
with the VEGFR-2 kinase activity. Also, it showed a 
great potential against in vivo developed prostate 
cancer model. The present study shows the 
importance of synthesizing chemical starting 
molecules which may have an impact on the 
pharmaceutical drug industry in its fight against 
cancer diseases. 
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